Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Endocyte Inc.

Apr 2009
Endocyte Inc. of West Lafayette, Ind., has initiated a randomized Phase II clinical study of its EC145 drug in women with platinum-resistant ovarian cancer. In addition to the drug, patients will be treated with the company’s EC20 molecular imaging agent, which enables clinicians to identify tumors that overexpress folate receptors.

BiophotonicsEndocyte Inc.molecular imagingNews & Features

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!